THE CLINICAL EFFICACY OF SEQUENTIAL USE OF GONADOTROPIN-RELEASING HORMONE ANALOG - LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN MEDICALLY ILL WOMEN WITH SYMPTOMATIC AND RELATIVELY LARGE ADENOMYOSIS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i9.26847Keywords:
Adenomyosis, Gonadotropin-releasing hormone analog, Levonorgestrel-releasing intrauterine systemAbstract
Objectives: To evaluate the clinical outcome of sequential therapy of gonadotropin-releasing hormone (GnRH) analog, followed by the levonorgestrel-releasing intrauterine system in medically ill women with relatively large and symptomatic adenomyosis.
Methods: A prospective cohorts study conducted in the Obstetrics and Gynaecology Department, Al-Yarmouk teaching hospital in Baghdad/Iraq from June 2016 to January 2018. 32 women, 40 years and above who complete their family and had significant medical disease along with symptomatic and relatively large adenomyosis (≥150 cm3) were included in the study. The primary outcome measure was to evaluate the clinical outcome of this sequential therapy in the form of improving menstrual blood loss and pelvic pain and the secondary outcome was decreasing uterine volume.
Results: There were significant improvements in both menstrual blood loss volume and dysmenorrhea at the end of the 1st year with p˂0.001, mainly in the first 6 months. There were also significant reductions in the uterine volume (197.2±30.7–91.5±6.0 mm3). The expulsion rate was 15.6%.
Conclusion: Sequential treatment protocol of GnRH agonist - LNG-IUS in symptomatic and relatively large adenomyosis (˃150 cm3) is effective in relieving symptoms and decreasing uterine volume with less possible expulsion rate, making the protocol good substitutions to surgery, especially in medically ill women were surgery carry more risk.
Downloads
References
Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20:511-21.
Benagiano G, Brosens I. History of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20:449-63.
Rapkin AJ, Nathan L. Pelvic pain and dysmenorrhea. In: Berek JS, Novak E, editors. Berek and Novak’s Gynaecology. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012. p. 470-504.
Garcia L, Isaacson K. Adenomyosis: Review of the literature. J Minim Invasive Gynecol 2011;18:428-37.
Grow DR, Filer RB. Treatment of adenomyosis with long-term GnRH analogues: A case report. Obstet Gynaecol 1991;78:538-9.
Lin J, Sun C, Zheng H. Gonadotropin-releasing hormone agonists and laparoscopy in the treatment of adenomyosis with infertility. Chin Med J 2000;113:442-5.
Dash S, Mishra J, Behera SS, Rout S. Therapeutic efficacy of levonorgestrel intrauterine system as an alternative to hysterectomy for management of heavy menstrual bleeding in perimenopausal women. Asian J Pharm Clin Res 2018;11:289-92.
Streuli I, Dubuisson J, Santulli P, de Ziegler D, Batteux F, Chapron C. An update on the pharmacological management of adenomyosis. Expert Opin Pharmacother 2014;15:2347-60.
Bahamondes L, Bahamondes MV, Shulman LP. Noncontraceptve benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update 2015;21:640-51.
Kauff-man RP. Review: Levonorgestrel IU system, OCPs, and antifibrinolytics each reduce bleeding in endometrial dysfunction. Ann Intern Med 2013;159:JC10.
Yun BH, Jeon YE, Seo SK, Ark JH, Yoon SO, Cho S, et al. E-ects of a levonorgestrel-releasing intrauterine system on the expression of steroid receptor coregulators in adenomyosis. Reprod Sci 2015;22:1539-48.
Cho S, Choi YS, Yun BH, Chon SJ, Jung YS, Kim H, et al. E-ects of levonorgestrel-releasing intrauterine system on lymphangiogenesis of adenomyosis. Am J Clin Pathol 2015;143:352-61.
Yoo HJ, Lee MA, Ko YB, Yang JB, Kang BH, Lee KH. The efficacy of the levonorgestrel-releasing intrauterine system in perimenopausal women with menorrhagia or dysmenorrhea. Arch Gynecol Obstet 2012;285:161-6.
Dartmouth K. A systematic review with meta-analysis: The common sonographic characteristics of adenomyosis. Ultrasound 2014;22:148 57.
Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97:734-9.
Dixon JS, Bird HA. Reproducibility along a 10 cm vertical visual analogue scale. Ann Rheum Dis 1981;40:87-9.
Verit FF, Yucel O. Endometriosis, leiomyoma and adenomyosis: The risk of gynecologic malignancy. Asian Pac J Cancer Prev 2013;14:5589 97.
Venugopalan SK, Pandian NS, Pavani M, Rao TS, Rajini Y, Khadeer SK, et al. Abnormal uterine bleeding in reproductive women: Diagnosis, management and treatment. Asian J Pharm Clin Res 2015;8:42-5.
Fedele L, Bianchi S, Raaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68:426-9.
Mateson KA, Rahn DD, Wheeler TL 2nd, Casiano E, Siddiqui NY, Harvie HS, et al. Society of gynecologic surgeons systematic review group. Nonsurgical management of heavy menstrual bleeding: A systematic review. Obstet Gynecol 2013;121:632-43.
Kelekci S, Kelekci KH, Yilmaza B. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis. Contraception 2012;86:458-63.
Zhang P, Song K, Li L, Yukuwab K, Kong B. Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis. Med Principle Pract 2013;22:480-3.
Lee KH, Kim JK, Lee MA, Ko YB, Yang JB, Kang BH, et al. Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis. Arch Gynecol Obstet 2016;294:561-6.
Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: A 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception J 2009;79:189-93.
Demir F, Desdicioglu R, Kelekci S. Assessment of -T-380A and levonorgestrel-releasing intrauterine device types in terms of partial and complete expulsion. Austin J Obstet Gynecol 2014;1.
Madden T, McNicholas C, Zhao Q, Secura GM, Eisenberg DL, Peipert JF. Association of age and parity with intrauterine device expulsion. Am Coll Obstet Gynecol 2014;124:718-26.
Peng FS, Wu MY, Yang JH, Chen SU, Ho HN, Yang YS. Insertion of the mirena intrauterine system for treatment of adenomyosis-associated menorrhagia: A novel method. Taiwan J Obstet Gynecol 2010;49:160 4.
Park DS, Kim ML, Song T, Yun BS, Kim MK, Jun HS, et al. Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis. Taiwanese J Obstet Gynecol 2015;54:412e-5.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
